Difference between revisions of "Aminoglutethimide (Cytadren)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Endocrine therapy" to "Category:Endocrine therapeutic") |
||
| Line 22: | Line 22: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Protein expression-specific medications]] | [[Category:Protein expression-specific medications]] | ||
| − | [[Category:Endocrine | + | [[Category:Endocrine therapeutic]] |
[[Category:Steroid synthesis inhibitors]] | [[Category:Steroid synthesis inhibitors]] | ||
[[Category:Aromatase inhibitors]] | [[Category:Aromatase inhibitors]] | ||
Revision as of 17:43, 3 February 2019
General information
Class/mechanism: Inhibitor of adrenalcortical steroid synthesis, blocks conversion of cholesterol to pregnenolone and subsequent synthesis of adrenal steroids, has aromatase inhibitor activity.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
Also known as
- Brand names: Cytadren, Orimeten, Orimetene